Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma


The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

“Once a patient relapses several times, they start running out of FDA-approved treatment options. And these new, both cellular and bispecific antibody, agents that are on the cusp of being approved are providing hope for those patients. In fact, the initial results from the studies are so promising that they are now being used or tested at least in earlier lines of treatment with combinations of other drugs that are being used to treat myeloma. And that's where our research comes in.”

Sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma following relapse after BiAb therapy, according to new research out of at Mount Sinai’s Tisch Cancer Institute published in Blood Advances.

CGTLive spoke with Samir Parekh, MD, director of translational research in myeloma and co-leader, Cancer Clinical Investigation program, The Tisch Cancer Institute, and member, Icahn Genomics Institute, Icahn School of Medicine, Mount Sinai, to learn more about the unmet needs for patients whose multiple myeloma relapses several times and the questions that remain to be investigated with sequential T cell redirection therapies.

Mouhieddine TH, Oekelen OV, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood Adv. Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923
Recent Videos
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
© 2024 MJH Life Sciences

All rights reserved.